David R. Spriggs

Q: What Schools Are Affiliated With David R. Spriggs

David R. Spriggs is affiliated with the following schools: Yale University, Icahn School of Medicine at Mount Sinai, Cornell University, Massachusetts General Hospital

David R. Spriggs's AcademicInfluence.com Rankings

David R. Spriggs

Philosophy

#9214

World Rank

#12741

Historical Rank

Logic

#6202

World Rank

#7693

Historical Rank

philosophy Degrees

David R. Spriggs

Biology

#12631

World Rank

#16121

Historical Rank

Immunology

#848

World Rank

#871

Historical Rank

Molecular Biology

#2071

World Rank

#2103

Historical Rank

Biochemistry

#2171

World Rank

#2316

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

David R. Spriggs's Degrees

PhD Biochemistry University of California, Berkeley
Doctorate Medicine Stanford University

Why Is David R. Spriggs Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David R. Spriggs's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Detection of circulating tumor necrosis factor after endotoxin administration. (1988) (1677)
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. (2002) (629)
Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. (1989) (472)
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. (2002) (458)
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. (1988) (358)
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. (1988) (334)
Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha. (1990) (307)
BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). (1998) (305)
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo (2015) (303)
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. (1997) (254)
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment (2017) (249)
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. (1988) (240)
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients (2012) (237)
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. (2010) (227)
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas (2010) (195)
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma (2012) (187)
Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. (1994) (180)
BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer (2013) (172)
Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. (1989) (170)
Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. (1987) (165)
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. (2002) (164)
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer (2015) (160)
Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. (1984) (159)
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. (2009) (159)
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. (1996) (152)
A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies (2008) (149)
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. (1996) (147)
The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee (2010) (145)
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma (2019) (137)
Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. (1987) (137)
Early detection and prognosis of ovarian cancer using serum YKL-40. (2004) (135)
Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen (2010) (133)
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. (1994) (133)
Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma (1989) (128)
Genomic structure, induction, and production of TNF-alpha. (1992) (123)
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. (2004) (121)
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2016) (121)
Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (2007) (120)
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. (2005) (113)
Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. (1997) (113)
Role of arachidonic acid metabolism in transcriptional induction of tumor necrosis factor gene expression by phorbol ester (1989) (113)
VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study (2007) (111)
Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function. (1984) (111)
Genomic complexity and AKT dependence in serous ovarian cancer. (2012) (110)
Effects of 1-β-d-Arabinofuranosylcytosine Incorporation on Elongation of Specific DNA Sequences by DNA Polymerase β (1988) (110)
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. (2002) (106)
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. (2002) (106)
Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. (1986) (103)
Tumor necrosis factor expression in human epithelial tumor cell lines. (1988) (101)
Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. (2002) (99)
Chronic TNF Infusion Causes Anorexia But Not Accelerated Nitrogen Loss (1989) (97)
Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand. (1987) (96)
Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine. (1984) (95)
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. (2007) (95)
Cytokine induction by 41.8 °C whole body hyperthermia (1995) (94)
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. (2011) (93)
Complications associated with intraperitoneal chemotherapy catheters. (2001) (92)
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. (2001) (92)
Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission (2008) (92)
Effect of tumor necrosis factor on GTP binding and GTPase activity in HL-60 and L929 cells. (1988) (85)
Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients. (1993) (84)
Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors (2009) (84)
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer (2018) (84)
Improved survival for BRCA2‐associated serous ovarian cancer compared with both BRCA‐negative and BRCA1‐associated serous ovarian cancer (2012) (80)
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. (2008) (80)
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. (2015) (79)
A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment. (1998) (78)
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors (2006) (77)
Non‐kinase second‐messenger signaling: new pathways with new promise (2004) (76)
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. (2007) (75)
Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor. (1990) (73)
Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside. (1985) (72)
Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. (1998) (70)
Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. (2006) (69)
Interleukin‐2 Initiates Metabolic Responses Associated with Critical Illness in Humans (1988) (68)
CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers (2009) (68)
Salvage weekly paclitaxel in recurrent ovarian cancer. (1997) (68)
Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors (2005) (68)
Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (2006) (67)
UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status. (1997) (66)
A phase I trial of perillyl alcohol in patients with advanced solid tumors (2003) (66)
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. (2007) (66)
Tumor necrosis factor expression by human ovarian carcinoma in vivo. (1991) (64)
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. (2007) (64)
Chemotherapy and total parenteral nutrition for advanced ovarian cancer with bowel obstruction. (1997) (64)
A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo. (1989) (61)
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. (1998) (61)
Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy. (1999) (60)
Incorporation of 9-beta-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. (1986) (58)
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. (2007) (56)
Tumor necrosis factor: still a promising agent. (1989) (56)
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma (2009) (56)
Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study (2006) (56)
Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial (2013) (55)
Presentation and subsequent publication rates of phase I oncology clinical trials (2005) (55)
More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. (2011) (51)
Intravenous aflibercept in patients with platinum‐resistant, advanced ovarian cancer: Results of a randomized, double‐blind, phase 2, parallel‐arm study (2014) (51)
Anthracyclines in the treatment of gynecologic malignancies. (2002) (51)
Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. (1995) (50)
Posttranscriptional regulation of protein expression in human epithelial carcinoma cells by adenine-uridine-rich elements in the 3'-untranslated region of tumor necrosis factor-alpha messenger RNA. (1997) (50)
The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. (1996) (50)
Multi‐institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S‐transferase P1‐1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer (2005) (49)
Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. (1998) (48)
Streptococcus agalactiae (group B) endocarditis — A description of twelve cases and review of the literature (1987) (48)
Novel Monoclonal Antibodies Against the Proximal (Carboxy-Terminal) Portions of MUC16 (2010) (46)
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. (2011) (46)
A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission (2007) (46)
Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. (2005) (46)
Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. (2003) (45)
Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies (2004) (45)
Optimal sequencing in the treatment of recurrent ovarian cancer. (2003) (44)
Cytokine Induction in Humans by 41.8 °C WholeBody Hyperthermia (1993) (42)
Effects of lipopolysaccharide on phospholipase A2 activity and tumor necrosis factor expression in HL-60 cells. (1990) (42)
Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer (2004) (41)
Clinical studies with tumour necrosis factor. (2007) (40)
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. (2014) (39)
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. (2003) (39)
Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma. (1998) (38)
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. (2003) (38)
Clinical pharmacology of low-dose cytosine arabinoside (1985) (38)
Biochemical and cellular pharmacology of cytosine arabinoside. (1985) (38)
PROGNOSTIC VALUE OF PRETREATMENT CA-125 IN ADVANCED OVARIAN CARCINOMA: A GYNECOLOGIC ONCOLOGY GROUP STUDY (2009) (38)
Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer (2005) (37)
Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion (2015) (36)
A concomitant ATP-depleting strategy markedly enhances anticancer agent activity (2001) (36)
Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer. (1997) (34)
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. (2006) (34)
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. (2010) (33)
Phospholipase C activates protein kinase C and induces monocytic differentiation of HL-60 cells. (1988) (33)
Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. (2005) (33)
Ovarian Cancer Treatment - Are We Getting Warmer? (2018) (33)
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. (2014) (33)
Prognosis of patients treated with whole-brain radiation therapy for metastatic gestational trophoblastic disease. (1998) (32)
Suramin‐induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans (1994) (31)
Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells. (1986) (31)
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission (2016) (31)
Effects of tiazofurin on protooncogene expression during HL-60 cell differentiation. (1988) (31)
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. (2012) (30)
Detection of 1-β-d-Arabinofuranosylcytosine Incorporation into DNA in Vivo (1987) (30)
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference (2019) (29)
Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study. (2003) (29)
Clinical and biologic effects of combination therapy with gamma‐interferon and tumor necrosis factor (1992) (29)
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer (2005) (28)
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. (2007) (28)
Cellular and clinical pharmacology of low-dose ara-C. (1985) (27)
Cytokine induction by 41.8 degrees C whole body hyperthermia. (1995) (26)
Salvage therapy for ovarian cancer. (1998) (26)
The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials (2012) (25)
Prolonged high dose ARA-C infusions in acute leukemia. (1988) (25)
Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. (2001) (24)
Detection of tumor necrosis factor gene expression at a cellular level in human acute myeloid leukemias. (1989) (24)
Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. (2017) (23)
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors (2015) (23)
The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients. (2001) (22)
Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 °C hyperthermia (1995) (22)
Consolidation for ovarian cancer in remission. (2006) (22)
High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. (1997) (21)
547 KOS-862 (Epothilone D): Phase 1 dose escalating and pharmacokinetic (PK) study in patients (Pts) with advanced malignancies (2003) (21)
Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. (2004) (21)
A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. (1994) (21)
Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812) (2004) (20)
Time to publication of oncology trials and why some trials are never published (2017) (20)
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. (2006) (20)
Clinical pharmacology of low-dose cytosine arabinoside. (1985) (19)
A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. (2007) (19)
A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer (2006) (18)
Recombinant Human Gamma Interferon Administered by Continuous Intravenous Infusion in Acute Myelogenous Leukemia and Myelodysplastic Syndromes (1993) (18)
Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results (2007) (18)
Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors. (2004) (17)
Treatment for Myelodysplastic Syndromes (1986) (17)
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer. (1999) (17)
Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. (2004) (17)
Taxol administered as a 120 hour infusion (1992) (17)
Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II). (1998) (16)
Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: a phase I and pharmacological study. (1985) (16)
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors (2007) (16)
Inhibition of murine erythroleukemia cell differentiation by 3-deazaadenosine. (1985) (15)
A pilot study of melphalan, tumor necrosis factor-α and 41.8 °C whole-body hyperthermia (1999) (15)
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells (2019) (15)
New agents for the treatment of ovarian cancer: the next generation (2005) (14)
Sequence-specific inhibition of DNA strand elongation by incorporation of 9-beta-D-arabinofuranosyladenine. (1989) (14)
Effects of 1-beta-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase beta. (1988) (14)
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors (2011) (14)
Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need (2011) (14)
PARP Inhibitors in Ovarian Cancer Treatment. (2016) (14)
Early CA‐125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy (2007) (13)
Progress in BRCA-Mutated Ovarian Cancer. (2018) (12)
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials (2015) (12)
Tumor necrosis factor, but not other hematopoietic growth factors, prolongs the survival of hairy cell leukemia cells. (1992) (12)
A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia. (1990) (12)
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities (2015) (12)
Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer. (2012) (12)
Dual-Fluorescence Isogenic High-Content Screening for MUC16/CA125 Selective Agents (2011) (12)
Cancer screening: how good is good enough? (2004) (12)
Rationale and clinical status of 41.8 degrees C systemic hyperthermia tumor necrosis factor, and melphalan for neoplastic disease. (1997) (11)
Cytokine induction in humans by 41.8 degrees C whole-body hyperthermia. (1993) (11)
Consolidation strategies in ovarian cancer: observations for future clinical trials. (2010) (11)
Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors (2005) (11)
Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies (2021) (11)
Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside. (1987) (11)
Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer. (1997) (10)
A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG162). (2004) (10)
Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo. (1987) (10)
Beyond the dose‐limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program (2016) (10)
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors (2011) (10)
Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer (2016) (10)
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. (2011) (9)
Galectins and Ovarian Cancer (2020) (9)
Effects of botulinum toxin type D on secretion of tumor necrosis factor from human monocytes (1989) (9)
Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look. (2000) (8)
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition (2021) (8)
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma (2012) (8)
Epothilones: better or more of the same? (2009) (7)
Phase I study of LY573636-sodium, an acylsulfonamide anti-cancer compound with a novel mechanism of action, administered as 24-hour continuous infusion in patients with advanced solid tumors (2007) (7)
PHASE I TRIALS WITH ORMAPLATIN (TETRAPLATIN) (1991) (7)
Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important? (2005) (7)
New drugs for ovarian cancer. (2011) (7)
Interleukin-12 armored chimeric antigen receptor (CAR) T cells for heterogeneous antigen-expressing ovarian cancer. (2018) (7)
A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma (2020) (7)
CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. (2012) (6)
Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 degrees C hyperthermia. (1995) (6)
Effects of cis-diamminedichloroplatinum on DNA incorporation and cytotoxicity of 1-beta-D-arabinofuranosylcytosine. (1986) (6)
Effects of tiazofurin on globin and proto-oncogene expression in K562 erythroleukemia cells. (1989) (5)
Low dose ara-C administered by continuous subcutaneous infusion: a pharmacologic evaluation. (1986) (5)
Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation. (2020) (4)
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee (2015) (4)
Drug development for chronic cancers: time to think differently? (2012) (4)
New drugs in gynecologic cancer (2001) (4)
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer (2018) (4)
Final results of a phase I study of picoplatin and pegylated liposomal doxorubicin in advanced solid tumor malignancies (2008) (4)
Somatic mutations in homologous recombination pathway genes in ovarian cancer. (2017) (4)
Paclitaxel and carboplatin (TP) for treatment of advanced or recurrent endometrial cancer: A retrospective study (2005) (4)
Phase I trial of PTK787/ZK222584 (PTK/ZK) in combination with carboplatin (C) and paclitaxel (T) in platinum-sensitive recurrent epithelial ovarian (EOC), fallopian tube (FT), or primary peritoneal (PPC) cancers (2007) (4)
Intraperitoneal chemotherapy (IPC) in older women with epithelial ovarian cancer (EOC). (2009) (4)
Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies (1993) (4)
Primary intravenous paclitaxel and platinum chemotherapy for high-risk Stage I epithelial ovarian carcinoma. (1999) (4)
CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting. (2016) (3)
Using patients as their own controls for cost evaluation of phase I clinical trials. (2004) (3)
Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study. (2001) (3)
Clinical Studies of Tumor Necrosis Factor in the USA (1992) (3)
Possible correlation between ormaplatin biotransformations and neurotoxicity. (1995) (3)
Chimeric antigen receptor (CAR) T cells genetically engineered to deliver IL-12 to the tumor microenvironment in ovarian cancer. (2017) (3)
Preliminary pharmacokinetics of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies (2004) (3)
Clinical Trials with Tumor Necrosis Factor (1990) (3)
Targeting NF-κB to Increase the Activity of Cisplatin in Solid Tumors (2005) (3)
Implementation of disease management guidelines in patients with advanced ovarian cancer. (1999) (3)
Uterine washing biomarkers as a novel screening tool for high-grade serous carcinoma (2013) (3)
Ovarian cancer as a chronic disease: a new treatment paradigm. Highlights of a roundtable discussion. (2001) (2)
Molecular pharmacology of cytosine arabinoside (1985) (2)
Effect of combination inhibition of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGF-R) on ovarian cancer cell lines. (2006) (2)
Identifying Clinical Improvement in Consolidation Single-Arm Phase 2 Trials in Patients With Ovarian Cancer in Second or Greater Clinical Remission (2012) (2)
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials (2018) (2)
Abstract 2033: Transcription factors that regulate MUC16 expression in ovarian cancer (2011) (2)
Abstract IA21: MUC16-directed immunotherapy for ovarian cancer (2020) (2)
Memorial Sloan-Kettering Cancer Center Experience with Intraperitoneal Chemotherapy of Ovarian Cancer (2000) (2)
Effect of modulation of the hostile tumor microenvironment through adoptive transfer of IL-12 expressing MUC-16 targeted T cells on ovarian tumors in vivo. (2012) (2)
A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia. (1999) (2)
Ovarian cancer staging: time for a closer look? (1998) (2)
Preliminary pharmacokinetics of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. (2004) (2)
Endometrial Stromal Sarcoma (2004) (2)
Reply to M.L. Friedlander et al. (2013) (1)
EFFICACY OF TLK286 (TELCYTA) ALONE AND INPARAPLATIN® OR DOXIL® (CAELYX®) IN PLATINUM RESISTANT OVARIAN CANCER – RESULTS FROM 3 PHASE 2 STUDIES (2004) (1)
Carboplatin hypersensitivity reactions (HSR) in carboplatin retreatment for recurrent ovarian cancer. (2015) (1)
BRCA1 immunohistochemistry in high-grade serous ovarian cancers (HGS-OC) characterized for BRCA1 germ-line mutations. (2012) (1)
Reply to M. Voskoboynik et al. (2014) (1)
Abstract 4332: Conditional transgenic mice for the carboxyl-terminus of MUC16 (2011) (1)
MUC16 gene up-regulates gene transcripts associated with cisplatin resistance in human ovarian cancer cells (2007) (1)
Blocking metastatic behavior of MUC16/CA-125-expressing cancer by targeting galectin-3 (2019) (1)
Addressing cervical cancer screening disparities through advances in artificial intelligence and nanotechnologies for cellular profiling. (2021) (1)
Effect of Mismatch Repair Status on Outcome of Early Stage Grade 1-2 Endometrial Cancer Treated With Vaginal Brachytherapy (2020) (1)
Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer (2005) (1)
Effect of Mismatch Repair Status on Outcome of Early-Stage Grade 1 to 2 Endometrial Cancer Treated With Vaginal Brachytherapy (2021) (1)
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions (1992) (1)
Abstract 1940: Successful eradication of established peritoneal ovarian tumors in SCID-beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen (2010) (0)
Abstract PR07: Reprogramming the tumor microenvironment with losartan to enhance immunotherapy of ovarian cancer (2020) (0)
Novel monoclonal antibodies detects external portion of the MUC16 in ovarian carcinoma (2008) (0)
Antibody-peptide epitope conjugates for personalized cancer therapy. (2021) (0)
Eukaryotic elongation factor 1 alpha 2 alone is not sufficient to cause tumorigenicity in immortalized and neoplastic ovarian cell lines. (2006) (0)
A multi-institutional retrospective analysis of immune checkpoint inhibitor efficacy in gynecologic cancers (2021) (0)
in Human K562 Erythroleukemia Cells by Arabinofuranosylcytosine (1984) (0)
Efficacy of a mitochondrial toxin, F16, in a multi-ATP-depleting regimen + chemotherapy on human breast cancer (MDA-MB-468) xenografts (2004) (0)
Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials of the National Institutes of Health Cancer Therapy Evaluation Program (CTEP). (2015) (0)
Abstract 513: Novel monoclonal antibody detects an intracellular portion of the MUC16 in ovarian carcinoma (2012) (0)
Enhanced Antitumor Efficacy of MUC-16 Targeted T Cells Further Modified to Constitutively Express the IL-12 Cytokine in a Syngeneic Model of Ovarian Cancer, (2011) (0)
Efficacy of a mitochondrial toxin, F16, in a multi-ATP-depleting regimen + chemotherapy on human breast cancer (MDA-MB-468) xenografts. (2004) (0)
Survival benefit for BRCA-associated epithelial ovarian cancer (OC) is not explained by primary platinum sensitivity alone (2008) (0)
Abstract 1946: Detecting protein-protein interactions between MUC16 CDΔ102 (80AA) and a SKOV-3 cDNA library using yeast two-hybrid screening (2011) (0)
Critical Questions in Ovarian Cancer Research and Treatment: Report of an AACR Special Conference (2019) (0)
Abstract 1828: Identification of MUC16/CA125-specific therapeutics through dual fluorescence high throughput screening (2012) (0)
132 A phase I and pharmacokinetic clinical trial of subcutaneous (sc) VEGF trap in advanced solid tumor patients (2004) (0)
Physician toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of 11,909 toxicities. (2015) (0)
923 Phase I study of taxol administered weekly in patients with persistent ovarian cancer (1995) (0)
Preclinical Development Dual-Fluorescence Isogenic High-Content Screening for MUC 16 / CA 125 Selective Agents (2011) (0)
Case 18-2019: A 24-Year-Old Woman with a Pelvic Mass. (2019) (0)
Abstract 2438: Loss of galectin 3 reveals its potential roles in the aggressive pathology of uterine serous carcinoma (2023) (0)
CA125 response to bevacizumab in recurrent ovarian cancer. (2010) (0)
Abstract 1836: Structural basis for recognition of MUC16 expressed in various cancers (2021) (0)
Phase I safety and immunogenicity study of NY-ESO-1b peptide and Montanide ISA-51 vaccination of patients with ovarian cancer (OC) in high risk first remission. (2006) (0)
Measuring Toxicity in Phase I Clinical Trials—Letter (2016) (0)
Abstract 1837: A human artificial chromosome (HAC)-based system as a powerful tool for stable co-expression of multiple proteins and therapeutic IgGs in mammalian cells (2021) (0)
A prospective, large-scale patient-reported outcomes program in patients with gynecologic malignancy (2020) (0)
Development of a high-affinity anti-galectin-3 antibody targeting interactions between MUC16/CA-125 and galectin-3 to inhibit oncogenic properties in serous ovarian cancer (2018) (0)
Abstract 141: MUC16/CA125 and Epithelial Growth Factor Receptor functionality in ovarian cancer (2015) (0)
Erratum to: Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma (2011) (0)
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer (2015) (0)
Comparative efficacy of bone marrow engraftment following high-dose carboplatin plus cyclophosphamide versus high-dose CBDCA/TAXOL , when rescued with Txl/cyclophosphamide and GCSF mobilized peripheral blood progenitor cells (1994) (0)
MUC16 antibodies and methods of use thereof (2011) (0)
Paclitaxel, carboplatin plus gemcitabine (PCG) as first-line treatment for advanced epithelial ovarian cancer (EOC): Pathologic complete response (pCR) and impact on cognitive functioning (2005) (0)
Abstract 3374: Development of novel and improved monoclonal antiMUC16 antibodies for the targeted therapy of ovarian cancer (2020) (0)
The MUC16 mucin gene upregulates gene transcripts associated with invasion (2007) (0)
228 A phase I trial of LY573636 in patients with advanced solid tumors (2004) (0)
Abstract 5587: Novel monoclonal antibodies block N-glycosylation Sites of the MUC16 ectodomain in ovarian carcinoma (2017) (0)
The safety and efficacy of bevacizumab therapy in recurrent ovarian carcinoma (2008) (0)
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials (2018) (0)
Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancer (2004) (0)
Is the Continual Reassessment Method superior to the standard 3+3 dose escalation scheme? (2008) (0)
Defining clinical and statistical improvement in consolidation single-arm trials in ovarian cancer. (2010) (0)
00082 NOVEL PROTEIN KINASE CS EPSILON AND DELTA HAVE AN IMPORTANT ROLE IN THE REGULATION OF SECRETION OF CA125 IN OVARIAN CANCER CELL LINES (2005) (0)
symposium article New drugs for ovarian cancer (2011) (0)
The interaction between human recombinant tumor necrosis factor — alpha and radiation in human carcinoma and sarcoma cell lines (1989) (0)
Effects ofBotulinum ToxinTypeD onSecretion ofTumorNecrosis Factor fromHumanMonocytes (1989) (0)
The impact of chemotherapy dose density among obese patients with ovarian cancer: A novel assessment of drug dosage relative to patient body surface area (2014) (0)
Bispecific engager immunotherapy targeting the retained portion of MUC16 (MUC16) is efficacious against ovarian cancer (2019) (0)
Investigational Drug Steering Committee Trial Design Task Force of the National Cancer Institute Therapeutics : Consensus Recommendations from the Clinical The Design of Phase II Clinical Trials Testing Cancer (2010) (0)
Tumor Necrosis Factor Expression by Human Ovarian Carcinoma in Vivo 1 (2006) (0)
LPAAT-B is a prognostic and therapeutic target in epithelial ovarian cancer (2004) (0)
A Phase 2 study of cisplatin analog CI-973 in the treatment of patients with refractory, advanced ovarian cancer (1995) (0)
Abstract 5503: Dual fluorescence high throughput screen detects MUC16 selective therapeutic candidates (2010) (0)
Abstract IA25: Strategies for glycosylation-based immunotargeting of MUC16 (2018) (0)
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer (2021) (0)
Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy (2006) (0)
Effect of enzalutamide (Enza) on androgen receptor (AR) positive (+) ovarian cancer. (2014) (0)
Advances in Brief BRCA 1 Up-Regulation Is Associated with Repair-mediated Resistance to m-Diamminedichloroplatinum ( II ) 1 (1998) (0)
40 Prognosis of patients treated with whole brain radiation therapy for metastatic gestational trophoblastic disease (1996) (0)
Pharmacokinetics of arsenic trioxide in patients with acute promyelocytic leukemia (1999) (0)
Abstract 3033: Identification of the MUC16/CA125 interaction network: Results of a high-throughput yeast two-hybrid screening (2012) (0)
Abstract 1776: High-affinity anti-galectin-3 antibodies targeting oncogenic properties in serous ovarian cancer (2018) (0)
Abstract PR08: Armored CAR T cells genetically modified to secrete IL-12 show enhanced efficacy and overcome a hostile tumor microenvironment in mouse ovarian peritoneal carcinomatosis (2017) (0)
Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. (2013) (0)
Phase II study of adjuvant gemcitabine plus docetaxel (GD) for completely resected stage I-IV high grade uterine leiomyosarcoma (HGuLMS) (2007) (0)
MUC16/CA125 specific targeting of critical signaling kinases in ovarian cancer. (2009) (0)
Impact of Prophylactic Conversion to an Extended Infusion Schedule to Prevent Hypersensitivity Reactions in Ovarian Cancer Patients during Carboplatin Retreatment (2015) (0)
Toxicity Attribution in Phase I Trials : Evaluating theEffectofDoseon theFrequencyofRelatedand Unrelated Toxicities (2016) (0)
best v70 year and model (2009) (0)
Abstract B222: MUC16/CA125 synthetic lethal kinase screen for novel ovarian cancer targets (2009) (0)
Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125 Selective Agents. (2022) (0)
Abstract LB-229: Utilizing a novel highly specific sialyl-Tn ELISA as a diagnostic for ovarian cancer (2019) (0)
Topoisomerase I inhibition in BRCA+ and BRCA- ovarian cancer (OC): A single-institution experience. (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David R. Spriggs?

David R. Spriggs is affiliated with the following schools:

David R. Spriggs's Academic­Influence.com Rankings

David R. Spriggs's Degrees

Why Is David R. Spriggs Influential?

David R. Spriggs's Published Works

Published Works

What Schools Are Affiliated With David R. Spriggs?

David R. Spriggs's AcademicInfluence.com Rankings